Who Paid My Doc
Tony Zhou
Clinical Informatics Brooklyn, NY Medical Doctor
NPI 1215381314 CMS profile 10092685
5517 7Th Ave Apt 1F, Brooklyn, NY 11220
General payments
$1,101
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Tony Zhou of Brooklyn, NY is reported in the CMS Open Payments database as having received $1,101 across 54 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $482 | 23 | |
| 2022 | General | $410 | 20 | |
| 2021 | General | $208 | 11 |
Beside peers
- Tony Zhou
- New York median
- Middle half of New York
- National median
In program year 2025, general payments to Tony Zhou were reported at $0. Among 69,423 New York profiles paid that year, the median was $180 and the middle half received between $58 and $640.
Show as a table
| Year | Tony Zhou | New York median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $175 | $53–$665 | $163 |
| 2020 | $0 | $122 | $37–$426 | $114 |
| 2021 | $208 | $144 | $44–$514 | $132 |
| 2022 | $410 | $160 | $51–$578 | $149 |
| 2023 | $482 | $170 | $54–$593 | $160 |
| 2024 | $0 | $173 | $56–$618 | $164 |
| 2025 | $0 | $180 | $58–$640 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 45 drugsPart D claims
1,409
Drug cost
$92,879
Branded share of claims
21%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Farxiga Dapagliflozin Propanediol | Brand | 19 | $17,927 | |
| Vascepa Icosapent Ethyl | Brand | 50 | $17,558 | |
| Jardiance Empagliflozin | Brand | 20 | $15,329 | |
| Januvia Sitagliptin Phosphate | Brand | 18 | $12,073 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 12 | $5,546 | |
| Diclofenac Sodium | Generic | 35 | $4,973 | |
| Shingrix Varicella-Zoster Ge/As01b/Pf | Brand | 20 | $3,810 | |
| Abrysvo Rsv Vacc, Pref A And Pref B/Pf | Brand | 13 | $3,615 | |
| Atorvastatin Calcium | Generic | 136 | $1,367 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 27 | $1,133 |
The 10 drugs with the highest cost, of 45 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 584 Part D prescribers listed as Preventive Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 27 billing codesPaid by Medicare
$3,722
Medicare patients
71
Services billed
304
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 72% | |
| Diabetes | 35% | |
| Arthritis | 25% | |
| Chronic kidney disease | 24% | |
| Osteoporosis | 23% | |
| COPD | 20% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
54 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Informatics in New York
Related records
Clinical Informatics in New York
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Informatics
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.